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JPGN  VObjectives: Detection of faecal gluten immunogenic peptides (GIP) is a
biomarker of recent gluten consumption. GIP levels can be used to monitor
gluten intake and compliment clinical methods to evaluate compliance to
gluten-free diet (GFD). In the present study, recent gluten intake was
measured by GIP in children with coeliac disease (CD) and compared to
routine clinical measures to evaluate GFD compliance.
Methods: GIP was measured in 90 samples from 63 CD children (44
previously and 19 newly diagnosed with follow-up samples at 6 and
12 months on GFD). Compliance to GFD was evaluated based on
clinical assessment, tissue transglutaminase (tTG) levels, and Biagi score.
Results: GIP was detectable in 16% of patients with previous CD diagnosis
on GFD. Body mass index z score (P¼ 0.774), height z score (P¼ 0.723),
haemoglobin concentration (P¼ 0.233), age (P¼ 0.448), sex (P¼ 0.734), or
disease duration (P¼ 0.488) did not differ between those with detectable and
nondetectable GIP. In newly diagnosed patients, on gluten-containing diet,
GIP was detectable in 95% of them. Following GFD initiation, GIP
decreased (P< 0.001); 17% and 27% had detectable levels at 6 and 12
months, respectively. Compared to GIP, the Biagi score, tTG, and clinical
assessment presented sensitivity of 17%, 42%, and 17%, respectively.
Likewise, GIP was detectable in 16%, 16%, and 14% of patients
evaluated as GFD compliant according to the Biagi score, tTG, and
clinical assessment, respectively. A combination of methods did not
improve identification of patients who were noncompliant.
Conclusions: Inclusion of faecal GIP measurements is likely to improve
identification of GFD recent noncompliance in CD management and could
be incorporated into current follow-up strategies.
Key Words: clinical assessment, coeliac disease, gluten-free diet, gluten
immunogenic peptides, tissue transglutaminase antibodies(JPGN 2018;67: 356–360)What Is Known
 Strict adherence to gluten-free diet is the only treat-
ment of coeliac disease.
 The precision of current clinical methods to ascertain
gluten-free diet compliance in coeliac disease
remains unclear.
 Gluten immunogenic peptides in faeces have been
proposed as a biomarker of gluten intake.
What Is New
 Gluten immunogenic peptide was detected in 16%
of coeliac disease patients on recommendation to
adhere to gluten-free diet.
 Using current clinical methods, almost 4 out of 5
children who do not comply with gluten-free diet will
be potentially missed.
 Inclusion of gluten immunogenic peptide in routine
practice may improve objective health professional
judgment and management of coeliac disease.reatment of coeliac disease (CD) relies on a lifelong, strictT gluten-free diet (GFD) which aims to ameliorate symptoms
and induce mucosal healing. Adherence to GFD is challenging to
maintain and can affect considerably a patient’s social interaction and
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JPGN  Volume 67, Number 3, September 2018 Faecal Gluten Immunogenic Peptide to Assess Gluten Intake in CDanthropometry, haematological profile, diet, serologicalmarkers, and
often validated questionnaires remains the standard approach to
assess compliance to GFD in the current clinical practice. Endoscopy
with small bowel biopsy is often reserved as last clinical resource to
ascertain intermediate adherence to GFD but is invasive, requires
general anaesthesia in paediatric patients, and interpretation findings
may be difficult considering the lag time to complete healing.
Among serological markers, the serum tissue transglutamin-
ase (tTG) titre is often used to ascertain compliance with GFD.
Although tTG levels have prime validity for disease diagnosis they
are relatively poor indicators of compliance with GFD (2). Simi-
larly, self-reported compliance questionnaires, such as the Biagi
score (3), based on the analysis of the strategy adopted by patients to
avoid gluten consumption, may suffer from recall bias and rely on
patient’s awareness of gluten-containing meals, including those
which use gluten as food additive and thus cannot preclude acci-
dental exposure to gluten. Hence, there is a strong interest in the
development of novel, objective biomarkers of GFD compliance.
Among them, the serum concentration of alkylresorcinols, phenolic
lipids which are present in the outer layers of wheat, rye, and barley
grains, has been proposed as a biomarker of gluten exposure (4).
Similarly, the average serum concentration of intestinal fatty acid–
binding protein (iFABP), a marker of intestinal epithelial damage, is
significantly elevated in patients with CD at diagnosis, associates
positively with Marsh histological scoring and decreases after
initiation of GFD (5). iFABP is also more sensitive than tTG
and deamidated gliadin peptide antibodies (DGP) to short-term
exposure to GFD (6), although other conditions can affect its serum
titre (7). Antibodies to DGP have also shown higher sensitivity than
tTG antibodies to monitor GFD compliance, but their screening
validity for CD diagnosis is inferior to the latter (8).
Beyond the blood biomarkers of compliance to GFD, detec-
tion of gluten immunogenic peptides (GIP) in faeces or urine has
recently been proposed as a sensitive and specific marker to detect
recent gluten intake (2) and has also been compared against
endoscopy and mucosal healing outcomes (9). The 33-mer peptide
from a2-gliadin is stable against breakdown by gastric, pancreatic,
and intestinal brush border membrane enzymes and quantification
in human faeces indicates recent gluten consumption (10). In a
dose-response study, consumption of as little as 100mg of gluten/
day gave detectable levels of GIP in faeces (10). Monitoring GIP in
faeces can therefore be used to monitor recent gluten intake and
cross-check the validity of current clinical approaches to ascertain
compliance to GFD.
The primary aim of the present study was to measure the
concentration of faecal GIP, as an objective biomarker of recent
gluten intake, in samples of children with CD before and while on
treatment with GFD and compare this with serological markers,
compliance questionnaires, and clinical assessment.SUBJECTS AND METHODS
As part of a cross-sectional study, which explored the role of
gut microbiota in CD, 90 fresh faecal samples were collected within
2 hours of passage and stored in808C from a convenience sample
of 63 consecutive children with CD who attended our local outpa-
tient clinic, between August 2011 and September 2013. Forty-four
samples were from children with previously diagnosed CD and 19
from patients with newly diagnosed CD on gluten-containing diet.
At follow-up, 12 and 15 of the newly diagnosed children provided
repeat samples at 6 and 12 months, respectively, while on treatment
with GFD. All patients were diagnosed according to the BSPGHAN
guidelines in place at the time, including small bowel endoscopy
with biopsy (1). Participants were not specifically aware that
measurements of GIP would be performed on their faecal sampleswww.jpgn.orgto minimize changes in their regular eating habits before sample
collection.
Faecal GIP was measured with the iVYLISA GIP Stool
ELISA kit (Biomedal, Spain) and according to the manufacturer’s
procedures. Patients were considered as compliant on GFD when
the faecal concentration of GIP was below the level of quantifica-
tion of the assay (ie, GIP <0.156mg/g sample).
For patients on GFD, compliance to GFD was evaluated as
‘‘good compliance’’ or ‘‘variable/noncompliant’’ by the clinical
dieticians (clinical assessment) running the outpatient clinic and
adopting a structured approach including extensive diet history,
changes in anthropometry, and recall of gastrointestinal symptoms
(Supplemental Text, Supplemental Digital Content 1, http://
links.lww.com/MPG/B434). Acquisition of diet history was per-
formed by senior specialist dieticians and encompassed a 30-
minute, face-to-face interview, with the child and carer, about
dietary habits and transgressions with regard to compliance to
GFD, using question prompting and a response-guided tactic.
Although blood samples were obtained on the day of the clinical
appointment for measurements of haematological profile and tTG
titres, results were available only after clinic and so did not
influence the dieticians’ judgment on compliance.
After their routine clinical appointment, the patients were
approached by a researcher, independent to the research team, who
asked them to complete the Biagi score (3). A Biagi score equal to
or greater than 3 was considered good compliance with GFD. For
newly diagnosed patients assessments were repeated at 6 and
12 months postdiagnosis.
Statistical Analysis
Changes in the concentration of faecal GIP within groups
were estimated using the general linear model with Box-Cox
transformation and considering sample dependency. Sensitivity,
specificity, and predictive values were calculated on cross-tabulated
data. For the purposes of the present study, sensitivity (ie, propor-
tion of patients with positive GIP correctly identified) and negative
predictive value were considered as the most clinically relevant
values to report. Interclass agreement between all methods and GIP
levels was evaluated using Cohen k statistics.
Ethical Considerations
Participants and their carers provided written informed con-
sent to participate in the study. The study and its procedures were
approved by theWest of Scotland Research Ethics Committee (Ref:
11-WS-0006) and the National Health Service Research and
Development office.
RESULTS
Gluten Immunogenic Peptide Levels Before
and After Introduction of Gluten-free Diet
Participant characteristics are presented inTable 1. In 7 of the 44
(16%) patients with previously diagnosed disease, GIP was detectable
indicating recent gluten consumption, and hence poor recent compli-
ance with GFD. In this group of patients, there was no difference in
body mass index z score (P¼ 0.774), height z score (P¼ 0.723),
haemoglobin concentration (P¼ 0.233), age (P¼ 0.448), sex
(P¼ 0.734), or disease duration (P¼ 0.488) between patients with
detectable and nondetectable GIP.
In 18 of 19 patients (95%) on gluten-containing diet under
investigation for CD diagnosis, a concentration of GIP was detect-
able and in all except for 1 patient tTG levels were raised. In the357
TABLE 1. Participant characteristics
Newly diagnosed
N¼ 19
Previously
diagnosed N¼ 44
Sex, males (%) 10 (53) 18 (43)
Age, y 10 (3.2) 9.3 (3.1)
Height z score, SD 0.05 (0.87) 0.01 (1.0)
BMI z score, SD 0.27 (1.12) 0.12 (1.1)
Disease duration, y n/a 4.6 (3.7)
Haemoglobin, g/dL 13.1 (9.4) 12.7 (8.6)
tTG antibodies, U/mL
At recruitment 69.7 (43.1) 5.6 (10.4)
%Raised 90% n/a
6-m follow up 9.8 (10)

n/a
%Raised 66% n/a
12-mo follow-up 6.9 (5.8)

n/a
%Raised 18% n/a
BMI ¼ body mass index; SD ¼ standard deviation; tTG ¼ tissue
transglutaminase antibodies.
P< 0.05 compared with concentration at recruitment.
FIGURE 2. Specificity, sensitivity, positive, and negative predictive
validity of clinical dietetic assessment, Biagi score, and tTG levels
compared with faecal GIP. GIP ¼ gluten immunogenic peptide;
NPV ¼ negative predictive value; PPV ¼ positive predictive value;
tTG¼ tissue transglutaminase antibodies.
Gerasimidis et al JPGN  Volume 67, Number 3, September 2018only patient with normal tTG the concentration of GIP was mar-
ginally above the limit of quantification of the assay. Following
diagnosis and recommendation to adhere to GFD, the serum tTG
decreased (Table 1) and as did the concentration of GIP; however, 2
of 12 patients (17%) and 4 of 15 (27%) patients had detectable
levels of GIP at 6 and 12 months, respectively (Fig. 1).
Biagi Score Compared With Faecal Gluten
Immunogenic Peptide Levels
Performance of the Biagi score was evaluated in a total of 65
data points from children with CD (previously diagnosed and newly
diagnosed on GFD) on recommendation to adhere to a GFD. Based
on the Biagi score, 61 (84%) of the assessments indicated compli-
ance to GFD; in total 12 samples (18.5%) had detectable levels of
GIP. The Biagi questionnaire presented a negative predictive value
of 84% to predict recent compliance to a GFD but 17% (2/12) of all
samples with detectable levels of GIP were identified correctlyFIGURE 1. Changes in the concentration of faecal GIP at the time of
diagnosis and at 6 and 12 month on gluten-free diet. 12_mo_GFD ¼
12months on gluten-free diet; 6_mo_GFD¼ 6months on gluten-free
diet; GIP ¼ gluten immunogenic peptide.
358(Fig. 2 and Supplemental Table, Supplemental Digital Content 2,
http://links.lww.com/MPG/B435). The interclass agreement
between the faecal GIP and the Biagi score was weak (k¼ 0.17).
Serum Tissue Transglutaminase Antibodies
Compared With Faecal Gluten Immunogenic
Peptide Levels
Sixty data points from children with CD on GFD (previously
diagnosed and newly diagnosed on GFD) were available to evaluate
serum tTG as proxy of GFD compliance. Based on normal (<7U/mL)
tTG levels, 44 (73%)patientswere assessed tobe adherent onGFD, and
in total 12 (20%) patients had detectable levels of faecal GIP. Classifi-
cationbasedon tTG levels presentedanegativepredictivevalueof84%
to detect recent compliance with GFD and 42% (5/12) of all patients
who were not compliant to GFD had raised levels of tTG (Fig. 2 and
SupplementalTable, SupplementalDigitalContent 2,http://links.lww.-
com/MPG/B435). There was no significant difference in the median
concentration of tTG between patients with detectable and nondetect-
able GIP levels (tTG 3.0 vs 3.6U/mL; P¼ 0.432). The interclass
agreement between the faecal GIP and tTG was weak (k¼ 0.17).
Clinical Dietetic Assessment Compared With
Gluten Immunogenic Peptide Levels
Data from 37 previously diagnosed children on treatment
with GFD (not including newly diagnosed patients at follow-up)
were available to evaluate the agreement between the dietician’s
clinical assessment and GIP analysis. Thirty-five (97%) of the
patients were assessed to be adherent on GFD based on the
dieticians reports; 6 (16%) patients had detectable faecal GIP.
Against this, clinical assessment had a negative predictive value
of 86% to predict compliance on GFD but only 1 of 6 (17%) of all
patients who were not compliant to GFD were assessed correctly
(Fig. 2 and Supplemental Table, Supplemental Digital Content 2,
http://links.lww.com/MPG/B435). The agreement between the fae-
cal GIP and clinical assessment was negligible (k¼ 0.18).
Composite Indices Versus Gluten Immunogenic
Peptide Levels
Composite indices including any 2 or all 3 of the GFD
compliance markers were produced for 33 patients on GFD andwww.jpgn.org
JPGN  Volume 67, Number 3, September 2018 Faecal Gluten Immunogenic Peptide to Assess Gluten Intake in CDwith all data available and compared against GIP levels. Combina-
tion of indices did not increase identification of patients who had a
recent consumption of gluten (ie, sensitivity) or the false negative
ratio. In contrast, inclusion of tTG, alone or in combination with any
of the other markers, decreased specificity and accordingly increased
the proportion of childrenwhowere falsely assessed as noncompliant
to recent consumption of gluten (Supplemental Figure, Supplemental
Digital Content 3, http://links.lww.com/MPG/B436).DISCUSSION
The present study shows that the current clinical approaches
to ascertain intake of gluten are likely to underperform. Almost 4
out of 5 children who do not comply with GFD will be missed, and
from the 10 children who will be assessed compliant with GFD, 2
will not be so. Inclusion of GIP may improve health professional
judgment and change current practice for selected patients. Con-
sidering early evidence to show that faecal GIP is sensitive enough
to detect small amounts of gluten intake (10), the results of this
study are in support of its clinical use as biomarker of recent gluten
intake and compliance to GFD, particularly when the aetiology of
refractory disease and accidental exposure needs to be ruled out and
before consideration of repeat endoscopy.
Faecal GIP levels were increased in almost all children who
on clinical assessment were consuming gluten to confirm disease
diagnosis, and as expected, GIP was below quantification level in
the large majority of patients following introduction of GFD. Still
approximately 18% of CD patients on recommendation to follow a
GFD, had recent consumption of gluten, a figure which is <30% of
participants with detectable GIP in a previous study in Spain of
older participants, including adults with CD (11).
The mainstay approach to evaluate compliance to GFD in
routine practice is clinical global assessment including serological
measurement of tTG, with repeat small bowel biopsy reserved for a
minority of the most difficult and refractory cases. In the research
setting, this is done and in addition checked with the use of
compliance questionnaires, such as the Biagi score, which we used
in the present study. Although the findings of this study suggest that
global clinical assessment, tTG, and Biagi score have a low false
negative ratio to identify patients who do not consume gluten,
their sensitivity to identify all patients who consume gluten wasClinical assessment
+/- Biagi score
Pt reports
non-compliance
+ve GIPGFD educaon
Pt re
comp
tTG remains raised or variable  
changes compared with previous 
measurements
Poor compliance
tTG decreasing compared with 
previous measurements
Good compliance likely
FIGURE 3. A decision pathway tomonitor GFD compliance for patients wit
gastrointestinal; GIP¼gluten immunogenic peptide; tTG ¼ tissue transgl
www.jpgn.orgrelatively poor. This prediction did not improve when we calculated
a composite index.
Among the methods we evaluated in this study, tTG
serology performed the best although more than 50% of the
patients noncompliant on GFD still remained undetected. Inter-
estingly, the specificity and positive predictive validity of tTG
was very low. This may be due to the long half-time for tTG to
normalize after the introduction of GFD, as also observed in the
present study, or the different time-frame of exposure to con-
sumption of gluten that each of these 2 biomarkers reflect. As
detectable faecal GIP occurs after 3 days of gluten consumption
(10) or within 4 to 6 hours when measurements in urine are
performed (9) this will be a useful biomarker for recent or
repeated incompliance to GFD. It will, however, not be good
marker to indicate intermittent compliance unless this occurs
close to the GIP test and for more than 3 days before faecal
sampling. In this context a negative GIP cannot ascertain long-
term compliance to GFD and serum tTG and clinical dietetic
assessment will be needed to complement this to evaluate both
long- and short-term adherence to GFD.
The analytical costs of GIP may incur an additional
expense to healthcare costs. Considering the overall treatment
costs, time involved, and the performance of current clinical
approaches to assess compliance to GFD, the introduction of GIP
as an assessment tool of GFD compliance may, however, reduce
health expenditure and improve patients care somewhat analo-
gous to the introduction of faecal calprotectin in patients with
inflammatory bowel disease. Both of these faecal tests are likely
to reduce the need for endoscopy, although not to the same
degree. In the present study we employed measurements of GIP
as the criterion standard method to evaluate recent consumption
of gluten and by inference a proxy marker of compliance to GFD.
Although faecal GIP is a novel biomarker, additional research is
needed to validate its usage in this context. Such research should
include dose-response studies, explore factors influencing inter
and intraindividual variations in GIP concentration, the effect
of consumption of very low, safe concentrations of gluten
from gluten-free products and comparison with mucosal biopsy
healing.
Comino et al (11) observed a positive association between
faecal GIP and DGP antibodies, although 87% of GIP-positive-ve GIP
+ve tTG
If persistent GI symptoms, 
anaemia, growth/weight concerns
Consider endoscopy
ports
liance
-ve tTG
Good compliance likely or
compliance close to GIP sampling
h coeliac disease (CD) in routine practice. GFD¼ gluten-free diet; GI¼
utaminase antibodies.
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Gerasimidis et al JPGN  Volume 67, Number 3, September 2018patients were negative for DGP antibodies. This suggests that use of
different GFD biomarkers is not interchangeable but rather com-
plementary. Hence, use of faecal GIP in conjunction with other
novel blood biomarkers such as serum alkylresorcinols, iFABP, and
DGP antibodies may improve evaluation of short-term and
medium-term compliance to GFD and presence on enterocyte
damage. This is particularly important to explore in future research
as measurement of faecal GIP or serum alkylresorcinols will reflect
recent dietary intake that patients may deliberately alter before
testing. In contrast, other markers such as the serum iFABP and
DGP antibodies will indicate medium-term adherence to GFD.
In the present study, noncompliance to a GFD was found to
be much lower when compared to other studies in the literature
(11,12). This may indicate sample selection bias; hence, the present
study is unable to comment on the true prevalence of patients who
do not comply with a GFD in routine clinical practice. Such
outcome was, however, beyond the primary scope of this study,
which was to assess the performance of routinely used GFD
compliance methods, individually and all together, against the
outcomes of GIP. For some patients, data were incomplete too,
particularly for the follow-up clinical dietetic assessments. This was
mainly due to 2 reasons. First some of the follow-up reviews of the
newly diagnosed patients were performed in other general hospitals
and by other health professionals, including general practitioners
and paediatric gastroenterologists. Second as the primary aim of the
present study was to explore the role of gut microbiota in CD and
the effect of GFD, the timing of the follow-up sample collection
from the newly diagnosed patients and hospital clinical assessments
did not always match.
In conclusion, the current approaches of evaluating adher-
ence to GFD could be improved and based on the novel findings of
the present study we advocate for the introduction of faecal
measurements of GIP to the routine management armamentarium
of CD and propose a decision pathway to monitor compliance of
GFD for patients with CD in routine practice (Fig. 3). Inclusion of
faecal GIP measurements will assist health professional judgment
based on objective measures and may reduce the need of
additional tests.360REFERENCES
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